From: Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma
Cell line
EGFR
HER2
MSLN
c-MET
B7-H3
SW1990
39.1
10.3
9.2
25.2
BxPC3
48.5
6.3
1.8
Capan 2
60.6
14.0
5.9
47.0
CFPAC-1
53.9
30.8
9.3
76.0
AsPC1
44.7
8.1
6.2
17.9
Panc1
65.9
21.4
5.2
12.3
32.4
Panc10.05
37.7
5.7
2.9
14.4